Should We Always Defer Treatment of Kidney Disease When There Is Extensive Interstitial Fibrosis on Biopsy?

Musab S. Hommos; Andrew D. Rule

doi:10.1159/000449513

Should We Always Defer Treatment of Kidney Disease When There Is Extensive Interstitial Fibrosis on Biopsy?

Musab S. Hommos, Andrew D. Rule

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Severity of interstitial fibrosis and tubular atrophy (IFTA) seen on kidney biopsy has been used by nephrologist as prognostic marker of kidney disease. While IFTA is a very strong predictor of kidney failure, some patients with severe fibrosis will still not progress to kidney failure within 5 years. Treatment of underlying kidney disease in select patients with severe IFTA should be considered when risks of treatment are reasonable despite the low potential for benefit.

Original language	English (US)
Pages (from-to)	286-288
Number of pages	3
Journal	American journal of nephrology
Volume	44
Issue number	4
DOIs	https://doi.org/10.1159/000449513
State	Published - Oct 1 2016

Keywords

Interstitial fibrosis
Kidney
Outcomes
Prognosis
Renal biopsy
Tubular atrophy

ASJC Scopus subject areas

Nephrology

Access to Document

10.1159/000449513

Fingerprint Dive into the research topics of 'Should We Always Defer Treatment of Kidney Disease When There Is Extensive Interstitial Fibrosis on Biopsy?'. Together they form a unique fingerprint.

Cite this

@article{bd86b288cb07476d8ea0564f713402f2,

title = "Should We Always Defer Treatment of Kidney Disease When There Is Extensive Interstitial Fibrosis on Biopsy?",

abstract = "Severity of interstitial fibrosis and tubular atrophy (IFTA) seen on kidney biopsy has been used by nephrologist as prognostic marker of kidney disease. While IFTA is a very strong predictor of kidney failure, some patients with severe fibrosis will still not progress to kidney failure within 5 years. Treatment of underlying kidney disease in select patients with severe IFTA should be considered when risks of treatment are reasonable despite the low potential for benefit.",

keywords = "Interstitial fibrosis, Kidney, Outcomes, Prognosis, Renal biopsy, Tubular atrophy",

author = "Hommos, {Musab S.} and Rule, {Andrew D.}",

note = "Funding Information: This paper was supported with funding from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (DK090358). Publisher Copyright: {\textcopyright} 2016 S. Karger AG, Basel. Copyright: All rights reserved.",

year = "2016",

month = oct,

day = "1",

doi = "10.1159/000449513",

language = "English (US)",

volume = "44",

pages = "286--288",

journal = "American Journal of Nephrology",

issn = "0250-8095",